


# **Effective Tumor Labeling of Pancreatic Cancer in a Patient Derived Orthotopic Xenograft Mouse Model using Fluorescent Humanized Anti-CEA Antibody**

Thinzar M. Lwin, MS MD


Takashi Murakami, MD, Paul J. Yazaki, PhD, Bryan Clary, MD,  
Robert M. Hoffman, Ph.D., Michael Bouvet, MD





# Margins in Oncologic Surgery




# Tumor Specific Fluorescence



# Selective Tumor Labeling of Pancreatic Cancer by Anti-CEA-IRDye800



# M5A-LICOR-IR800 in a Patient Derived Orthotopic Xenograft Model (PDOX)



# Features

- Humanized anti-CEA antibody
- IRDye800
- Patient derived orthotopic xenograft of pancreatic cancer
- Bright and specific in-situ entire tumor labeling
- Potential for tumor-specific fluorescence guided surgery

# Acknowledgements



**UC San Diego**  
MOORES CANCER CENTER



**Mount  
Sinai  
Beth Israel**




UCSD, Cancer  
Therapeutics Training  
Program:

**T32 CA 121938-10**



**Dr Michael Bouvet**  
UCSD, Moores  
Cancer Center



**Dr Robert Hoffman**  
Anticancer Inc.




**Dr Paul Yazaki**  
City of Hope,  
Beckman Research  
Institute



**Dr Jonathan de Long**  
UCSD, Bouvet lab &  
Center for Future of  
Surgery



**Dr Steven Dowdy**  
UCSD, Cellular and  
Molecular Medicine



**Dr Stephen Howell**  
UCSD, Moores  
Cancer Center  
CT2 Program Director